These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1456 related articles for article (PubMed ID: 31754328)

  • 1. Current Progress in CAR-T Cell Therapy for Solid Tumors.
    Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q
    Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
    Alcantara M; Du Rusquec P; Romano E
    Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors.
    Date V; Nair S
    Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
    Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
    Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
    Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
    Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
    J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma.
    Ali S; Kjeken R; Niederlaender C; Markey G; Saunders TS; Opsata M; Moltu K; Bremnes B; Grønevik E; Muusse M; Håkonsen GD; Skibeli V; Kalland ME; Wang I; Buajordet I; Urbaniak A; Johnston J; Rantell K; Kerwash E; Schuessler-Lenz M; Salmonson T; Bergh J; Gisselbrecht C; Tzogani K; Papadouli I; Pignatti F
    Oncologist; 2020 Feb; 25(2):e321-e327. PubMed ID: 32043764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas.
    Ahmad A; Uddin S; Steinhoff M
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
    Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
    J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of Chimeric Antigen Receptor T-cell Therapy in Adults.
    Dudley CV; Baer B; Simons RM
    Semin Oncol Nurs; 2019 Oct; 35(5):150930. PubMed ID: 31561845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CAR T-Cells.
    Nair R; Westin J
    Adv Exp Med Biol; 2020; 1244():215-233. PubMed ID: 32301017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current Progress in CAR-T Cell Therapy for Hematological Malignancies.
    Han D; Xu Z; Zhuang Y; Ye Z; Qian Q
    J Cancer; 2021; 12(2):326-334. PubMed ID: 33391429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.
    Subklewe M; von Bergwelt-Baildon M; Humpe A
    Transfus Med Hemother; 2019 Feb; 46(1):15-24. PubMed ID: 31244578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment.
    Zhao Z; Xiao X; Saw PE; Wu W; Huang H; Chen J; Nie Y
    Sci China Life Sci; 2020 Feb; 63(2):180-205. PubMed ID: 31883066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
    Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L
    Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.